Q2 Earnings Scorecard And Stock Reports For JNJ, Coke & Honeywell
Zacks Investment Research | Jul 20, 2017 12:36AM ET
Thursday, July 20, 2017
The Zacks Research Daily features the best research output of our analyst team. In today’s write-up, we are featuring analyst reports on 16 major stocks, including reports on Johnson & Johnson (NYSE:JNJ), Coca-Cola (KO), and Honeywell (HON). These reports have been hand-picked from amongst the 70 or so stock research reports published by our analyst team today.
You can see all of today’s research reports here >>
In addition to these stock research reports, we are also giving you a real-time scorecard of the ongoing Q2 earnings season where 16 S&P 500 members reported results this morning and a further 9 index members, including Microsoft (NASDAQ:MSFT) and Visa, on deck to report after the market’s close today.
You can read more about our views about this earnings season in the weekly Earnings Trends report >>>> Earnings Season Off to a Good Start
Q2 Earnings Scorecard (as of Thursday, July 20th)
Including all of this morning’s releases, we now have Q2 results from 76 S&P 500 members that combined account for 21.1% of the index's total market capitalization. Total earnings for these 76 index members are up +8.6% on +5,4% higher revenues, with 75% beating EPS estimates and 71.1% beating revenue estimates. The proportion of companies beating both EPS and revenue estimates is 56.6%.
The comparison charts below help put the Q2 results thus far in historical context.
As you can see, the Q2 earnings growth (+8.6%) is tracking below what this same group of companies achieved in the preceding period (+16.5%), but is otherwise notably above the 4- and 12-quarter average levels. Importantly, there is clear momentum on the revenue side, both in terms of growth as well as positive surprises. Not only is the Q2 revenue growth (+5.4%) on par with the growth pace of the preceding period, but notably above what we have been seeing in recent quarters.
You can see in the chart below the proportion of companies beating both EPS and revenue estimates.
Get The News You Want
Plenty of Q2 reports are still to come. But there is no question that are off to a good and reassuring start in this reporting cycle.
Today’s Featured Research Reports
Buy rated Johnson & Johnson shares have gained +17.4% year to date, outperforming the large-cap pharma space (up +12.2%). J&J reported mixed Q2 results, beating on earnings but missing on sales. However, J&J is optimistic that sales growth will accelerate in 2H17. Though headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain, the Zacks analyst thinks new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to J&J’s growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. However, sluggish growth in the Consumer segment due to category slowdown is a concern.
(You can ) .
Shares of Coca-Cola have gained +8.1% in the year-to-date period underperforming the Zacks Consumer Staples sector as a whole, which has gained +9.5%. The Zacks analyst likes Coca-Cola’s increased marketing investments, which are driving volume growth in stable markets like North America. Moreover, the company is on track to achieving total annualized productivity saving target of approximately $3.8 billion by 2019. Also, Coca-Cola’s new revenue platforms should drive growth over the long term. However, the top line needs to show sustained improvement. Coca-Cola’s sales are being weighed down by declining demand in certain emerging and developing markets and shift in consumer preference. Also, severe macroeconomic challenges in certain international markets and the stronger U.S. dollar have impacted results for the cola giant, which generates about half of its sales abroad.
(You can ) .
Buy rated Honeywell’s shares have outperformed the diversified operations industry gaining +17.5% vs. +2.3% in the year-to-date period. The Zacks analyst like the company’s continuing efforts on increasing its presence in high-growth regions. Additionally it is building a robust pipeline of new products and has regularly fine-tuned its portfolio to focus on core businesses. Diligent focus on working capital management, free cash flow generation and a conservative balance sheet remain key positive attributes. Earnings for 2017 are expected to be up 7–10% year over year to $6.90–$7.10 per share on favorable growth dynamics. However, adverse foreign currency translations, high R&D expenses to fend off competition and volatility in commodity prices related to the Brexit referendum are likely to peg back Honeywell’s growth momentum to some extent.
(You can ) .
Other noteworthy reports we are featuring today include Cummins (CMI), Crown Castle (CCI) and WEC Energy (WEC).
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
.
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst believes improving economic conditions in its service territories is boosting demand and synergies from acquisitions will continue to drive performance of the company.
Per the Zacks analyst, wireless and consumer subscriber additions is a major positive for Shaw Communications, while a competitive Canadian wireless market raises concern.
Per the covering analyst, the recent acquisition of over 28,000 route miles of fiber will help Crown Castle's efforts diversify into the fiber business.
Per the Zacks Analyst, HubSpot benefits from the growing adoption of One HubSpot initiative, cross-selling opportunities, and expanding international footprint.
Per the Zacks analyst higher commissions and fees will continue to boost revenues for Brown & Brown, thereby accelerating the company's overall growth. But, rising expenses continue to raise concerns.
While Interactive Brokers' focus on Electronic Brokerage segment will aid its financials, the Zacks analyst believes that the same will lead to a rise in severance and other restructuring costs.
Per the covering analyst, Fortune Brands will gain from growth in U.S. home products market.
The Zacks analyst believes improving economic conditions in its service territories is boosting demand and synergies from acquisitions will continue to drive performance of the company.
Per the Zacks analyst, wireless and consumer subscriber additions is a major positive for Shaw Communications, while a competitive Canadian wireless market raises concern.
Per the covering analyst, the recent acquisition of over 28,000 route miles of fiber will help Crown Castle's efforts diversify into the fiber business.
Per the Zacks Analyst, HubSpot benefits from the growing adoption of One HubSpot initiative, cross-selling opportunities, and expanding international footprint.
Per the Zacks analyst higher commissions and fees will continue to boost revenues for Brown & Brown, thereby accelerating the company's overall growth. But, rising expenses continue to raise concerns.
While Interactive Brokers' focus on Electronic Brokerage segment will aid its financials, the Zacks analyst believes that the same will lead to a rise in severance and other restructuring costs.
Per the covering analyst, Fortune Brands will gain from growth in U.S. home products market.
New Upgrades/h6
Healthy relationship with national oil companies along with diversified product portfolio and geographical presence accounts for McDermott's impressive backlog and revenues, per the Zacks analyst.
Per the covering analyst, updated 2017 revenue guidance across all segments is aiding Cummins. Also, the transition to new emission standards in various locations is boosting the company's results.
Yum! Brands' focus on the development of its three iconic global brands, increasing franchise ownership and creating a leaner and efficient cost structure should drive growth, per the Zacks analyst.
Healthy relationship with national oil companies along with diversified product portfolio and geographical presence accounts for McDermott's impressive backlog and revenues, per the Zacks analyst.
Per the covering analyst, updated 2017 revenue guidance across all segments is aiding Cummins. Also, the transition to new emission standards in various locations is boosting the company's results.
Yum! Brands' focus on the development of its three iconic global brands, increasing franchise ownership and creating a leaner and efficient cost structure should drive growth, per the Zacks analyst.
New Downgrades/h6
The Zacks analyst believes that stuttering operations in Libya, which, apart from being a low-cost base, once made up 11% of Marathon Oil (NYSE:MRO)'s total output, will cause the shares to underperform.
Per the covering analyst, sluggish consumer beauty segment, competitive pressure, currency headwinds and changing consumer preferences have been the concerns, which might weigh on Coty's results.
The Zacks analyst is concerned about the recall of AngioDynamics Acculis Microwave Tissue Ablation System in the oncology segment. Furthermore, the company sees earnings to fall sequentially in FY18.
The Zacks analyst believes that stuttering operations in Libya, which, apart from being a low-cost base, once made up 11% of Marathon Oil (NYSE:MRO)'s total output, will cause the shares to underperform.
Per the covering analyst, sluggish consumer beauty segment, competitive pressure, currency headwinds and changing consumer preferences have been the concerns, which might weigh on Coty's results.
The Zacks analyst is concerned about the recall of AngioDynamics Acculis Microwave Tissue Ablation System in the oncology segment. Furthermore, the company sees earnings to fall sequentially in FY18.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.